Article: Ciphergen Test Shows Promise For Detection Of Ovarian Cancer.

Senior Staff Writer

Shareholders of Ciphergen Biosystems Inc. watched the stock climb 21.4 percent Monday on news that the company's technology looked promising in detecting early stage ovarian cancer.

The Fremont, Calif.-based firm said its ProteinChip System was used to discover three protein biomarkers that, when combined, form the basis of a clinical assay designed to detect Stage I/II ovarian cancer. Each of the proteins was sequenced and identified with the use of the ProteinChip System. Two are cleaved products of precursor proteins and are present in the serum at a fraction of the concentration of their corresponding full-length proteins. The ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!